Monitor Nasdaq's determination on regained compliance and the negotiation of definitive agreements with AHA and Cleveland Clinic Weston. The conversion cap and beneficial ownership limitation may limit near-term dilution, but stockholder approval for the full 80M share conversion is a key catalyst.
Price Chart
Executive Summary
Vivos Therapeutics closed its acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test, issuing $12M in Series C Convertible Preferred Stock (convertible at $0.15/share into up to 80M common shares). The deal is expected to add >$10M to stockholders' equity, potentially curing a Nasdaq minimum equity deficiency, but creates massive potential dilution (~238% of current shares outstanding) and all revenue projections are contingent on unsecured future agreements and clinical validation.
Key Financial Metrics
Key Facts
- Vivos issued 12,000 shares of Series C Convertible Preferred Stock with aggregate stated value of $12 million to acquire 11% of SOD Sciences and 50% of the pseudohypoxia test.
- Preferred stock is convertible at $0.15/share into up to 80 million common shares, subject to a 19.99% exchange cap and 4.99% beneficial ownership limitation.
- Expected increase in stockholders' equity of more than $10 million, potentially curing Nasdaq's $2.5 million minimum equity deficiency.
- No cash consideration was paid; all revenue from AHA channel, Cleveland Clinic, and test sales is contingent on future definitive agreements and clinical validation.
- AHA channel is subject to bankruptcy court approval; AHA is in pending bankruptcy proceedings.
Financial Impact
$12 million in preferred stock issued; expected equity increase >$10 million; potential dilution up to 80 million shares (approximately 238% of current shares outstanding).
Risk Factors
- Massive potential dilution from conversion of Series C Preferred into up to 80 million common shares.
- All revenue projections are contingent on unsecured future agreements, clinical validation, and bankruptcy court approval for AHA channel.
- Nasdaq may not concur that the company has regained compliance with the stockholders' equity requirement.
- The pseudohypoxia test has not been clinically validated or FDA-cleared; the press release explicitly states it does not establish that the test predicts any conditions.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383925 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1310 (−2.75%) |
Oct 19, 2026 7d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1310 (−7.09%) |
Oct 19, 2026 7d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1310 (−6.83%) |
Oct 15, 2026 11d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Oct 15, 2026 11d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1310 (−8.26%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1310 (+12.08%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1310 (−41.75%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1310 (−52.67%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1310 (+56.51%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1310 (−61.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers